CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Shiva Pharmachem Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Shiva Pharmachem Ltd
9Th Floor Abs Towersold Road
Phone: +91 2652321418p:+91 2652321418 VADODARA, 390023  India Fax: +91 2652357238f:+91 2652357238

Business Summary
Shiva Pharmachem Ltd is an India-based company. The Company is engaged in manufacturing of acid and alkyl chlorides, by volume, in India and a key player globally. The Company’s product categories include acid chlorides, fatty acid chlorides, alkyl chlorides, pharma intermediates, and specialty chemicals, agrochemicals, and nitriles.
(Source: 10-K405)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/20233/31/2023Yes----

General Information
Number of Employees: 864 (As of 3/31/2023)
Outstanding Shares: 106,203,000 (As of 3/31/2023)
Shareholders: 9
Fax Number: +91 2652357238


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, December 3, 2024